Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells

被引:31
|
作者
Panieri, Emiliano [1 ]
Saso, Luciano [1 ]
机构
[1] Univ Roma La Sapienza, Dept Physiol & Pharmacol Vittorio Erspamer, I-00185 Rome, Italy
关键词
NRF2-KEAP1; NRF2; inhibitors; reactive oxygen species; oxidative stress; cancer; chemotherapy; redox therapy;
D O I
10.1089/ars.2020.8146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Significance: The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1) pathway is a crucial and highly conserved defensive system that is required to maintain or restore the intracellular homeostasis in response to oxidative, electrophilic, and other types of stress conditions. The tight control of NRF2 function is maintained by a complex network of biological interactions between positive and negative regulators that ultimately ensure context-specific activation, culminating in the NRF2-driven transcription of cytoprotective genes. Recent Advances: Recent studies indicate that deregulated NRF2 activation is a frequent event in malignant tumors, wherein it is associated with metabolic reprogramming, increased antioxidant capacity, chemoresistance, and poor clinical outcome. On the other hand, the growing interest in the modulation of the cancer cells' redox balance identified NRF2 as an ideal therapeutic target. Critical Issues: For this reason, many efforts have been made to identify potent and selective NRF2 inhibitors that might be used as single agents or adjuvants of anticancer drugs with redox disrupting properties. Despite the lack of specific NRF2 inhibitors still represents a major clinical hurdle, the researchers have exploited alternative strategies to disrupt NRF2 signaling at different levels of its biological activation. Future Directions: Given its dualistic role in tumor initiation and progression, the identification of the appropriate biological context of NRF2 activation and the specific clinicopathological features of patients cohorts wherein its inactivation is expected to have clinical benefits, will represent a major goal in the field of cancer research. In this review, we will briefly describe the structure and function of the NRF2/ KEAP1 system and some of the most promising NRF2 inhibitors, with a particular emphasis on natural compounds and drug repurposing.
引用
收藏
页码:1428 / 1483
页数:56
相关论文
共 50 条
  • [1] The NRF2/KEAP1 Axis in the Regulation of Tumor Metabolism: Mechanisms and Therapeutic Perspectives
    Panieri, Emiliano
    Telkoparan-Akillilar, Pelin
    Suzen, Sibel
    Saso, Luciano
    BIOMOLECULES, 2020, 10 (05)
  • [2] The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases
    Deshmukh P.
    Unni S.
    Krishnappa G.
    Padmanabhan B.
    Biophysical Reviews, 2017, 9 (1) : 41 - 56
  • [3] Nestin is essential for cellular redox homeostasis and gastric cancer metastasis through the mediation of the Keap1–Nrf2 axis
    Jing Lv
    Meiqiang Xie
    Shufen Zhao
    Wensheng Qiu
    Shasha Wang
    Manming Cao
    Cancer Cell International, 21
  • [4] Nrf2 activation through the inhibition of Keap1–Nrf2 protein–protein interaction
    Sumi Lee
    Longqin Hu
    Medicinal Chemistry Research, 2020, 29 : 846 - 867
  • [5] Dysregulation of Nrf2/Keap1 Redox Pathway in Diabetes Affects Multipotency of Stromal Cells
    Rabbani, Piul S.
    Soares, Marc A.
    Hameedi, Sophia G.
    Kadle, Rohini L.
    Mubasher, Adnan
    Kowzun, Maria
    Ceradini, Daniel J.
    DIABETES, 2019, 68 (01) : 141 - 155
  • [6] Cellular Modulators of the NRF2/KEAP1 Signaling Pathway in Prostate Cancer
    Tossetta, Giovanni
    Fantone, Sonia
    Marzioni, Daniela
    Mazzucchelli, Roberta
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (07):
  • [8] Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells
    Zhou, Bo
    Zhang, Xiaolei
    Wang, Guiren
    Barbour, Karen W.
    Berger, Franklin G.
    Wang, Qian
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (01) : 92 - 99
  • [9] The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease
    Geertsema, Sem
    Bourgonje, Arno R.
    Fagundes, Raphael R.
    Gacesa, Ranko
    Weersma, Rinse K.
    van Goor, Harry
    Mann, Giovanni E.
    Dijkstra, Gerard
    Faber, Klaas N.
    TRENDS IN MOLECULAR MEDICINE, 2023, 29 (10) : 830 - 842
  • [10] Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway
    Tossetta, Giovanni
    Marzioni, Daniela
    PHARMACOLOGICAL RESEARCH, 2022, 183